Tags

Type your tag names separated by a space and hit enter

Myelin-oligodendrocyte-glycoprotein (MOG) autoantibodies as potential markers of severe optic neuritis and subclinical retinal axonal degeneration.
J Neurol 2017; 264(1):139-151JN

Abstract

Antibodies against conformation-dependent epitopes of myelin-oligodendrocyte-glycoprotein (MOG-abs) are present in subgroups of neuromyelitis optica spectrum disorder (NMOSD), recurrent optic neuritis (rON), multiple sclerosis (MS), and anti-NMDAR encephalitis. Using optical coherence tomography (OCT) we assessed whether MOG-abs might serve as potential marker of retinal axonal degeneration. We investigated a clinically heterogeneous cohort of 13 MOG-abs-positive patients (4 MOG-abs-positive rON, 4 MOG-abs-positive adult MS, 3 MOG-abs-positive relapsing encephalomyelitis, 2 MOG-abs-positive aquaporin-4-abs-negative NMOSD). As controls, we studied 13 age, sex and ON episode(s)-matched MOG-abs and aquaporin-4-abs-negative (AQP4-abs-negative) MS patients and 13 healthy controls (HC). In addition, we investigated 19 unmatched AQP4-abs-positive MOG-abs-negative NMOSD subjects. Considering all eyes, global pRNFL [in µm, mean (SD)] was significantly reduced in MOG-abs-positive patients [72.56 (22.71)] compared to MOG-abs-negative MS [80.81 (13.55), p = 0.0128], HCs [103.54 (8.529), p = 0.0014] and NMOSD [88.32 (18.43), p = 0.0353]. Non ON eyes from MOG-abs-positive subjects showed significant subclinical atrophy of temporal pRNFL quadrants. Microcystic macular edema (MME) was observed only in eyes of MOG-abs-positive (24%) and AQP4-abs-positive NMOSD (5.6%), but not in MOG-abs-negative MS or HC (p < 0.01). MOG-abs may serve as potential marker of retinal degeneration. Specifically, MOG-abs-related OCT features predominate in temporal pRNFL quadrants (resembling the MS retinal pattern), might be more severe than AQP4-abs-positive NMOSD, indicate subclinical pathology, and may be associated with MME.

Authors+Show Affiliations

Institute of Clinical Neuroimmunology, Biomedical Center and University Hospital, Ludwig-Maximilians Universitaet Muenchen, Munich, Germany. joachim.havla@med.lmu.de.Institute of Clinical Neuroimmunology, Biomedical Center and University Hospital, Ludwig-Maximilians Universitaet Muenchen, Munich, Germany.Institute of Clinical Radiology, Ludwig-Maximilians Universitaet Muenchen, Munich, Germany.Institute of Clinical Neuroimmunology, Biomedical Center and University Hospital, Ludwig-Maximilians Universitaet Muenchen, Munich, Germany.Institute of Clinical Neuroimmunology, Biomedical Center and University Hospital, Ludwig-Maximilians Universitaet Muenchen, Munich, Germany.Institute of Clinical Neuroimmunology, Biomedical Center and University Hospital, Ludwig-Maximilians Universitaet Muenchen, Munich, Germany.Institute of Clinical Neuroimmunology, Biomedical Center and University Hospital, Ludwig-Maximilians Universitaet Muenchen, Munich, Germany. Munich Cluster for Systems Neurology, Munich, Germany.Institute of Clinical Neuroimmunology, Biomedical Center and University Hospital, Ludwig-Maximilians Universitaet Muenchen, Munich, Germany. Department of Neurology, Roger Salengro Hospital, University of Lille, Lille, France.

Pub Type(s)

Journal Article

Language

eng

PubMed ID

27844165

Citation

Havla, Joachim, et al. "Myelin-oligodendrocyte-glycoprotein (MOG) Autoantibodies as Potential Markers of Severe Optic Neuritis and Subclinical Retinal Axonal Degeneration." Journal of Neurology, vol. 264, no. 1, 2017, pp. 139-151.
Havla J, Kümpfel T, Schinner R, et al. Myelin-oligodendrocyte-glycoprotein (MOG) autoantibodies as potential markers of severe optic neuritis and subclinical retinal axonal degeneration. J Neurol. 2017;264(1):139-151.
Havla, J., Kümpfel, T., Schinner, R., Spadaro, M., Schuh, E., Meinl, E., ... Outteryck, O. (2017). Myelin-oligodendrocyte-glycoprotein (MOG) autoantibodies as potential markers of severe optic neuritis and subclinical retinal axonal degeneration. Journal of Neurology, 264(1), pp. 139-151. doi:10.1007/s00415-016-8333-7.
Havla J, et al. Myelin-oligodendrocyte-glycoprotein (MOG) Autoantibodies as Potential Markers of Severe Optic Neuritis and Subclinical Retinal Axonal Degeneration. J Neurol. 2017;264(1):139-151. PubMed PMID: 27844165.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Myelin-oligodendrocyte-glycoprotein (MOG) autoantibodies as potential markers of severe optic neuritis and subclinical retinal axonal degeneration. AU - Havla,Joachim, AU - Kümpfel,T, AU - Schinner,R, AU - Spadaro,M, AU - Schuh,E, AU - Meinl,E, AU - Hohlfeld,R, AU - Outteryck,O, Y1 - 2016/11/14/ PY - 2016/07/22/received PY - 2016/11/03/accepted PY - 2016/11/02/revised PY - 2016/11/16/pubmed PY - 2017/4/11/medline PY - 2016/11/16/entrez KW - Microcystic macular edema KW - Multiple sclerosis KW - Myelin-oligodendrocyte-glycoprotein KW - Neuromyelitis optica spectrum disorder KW - Optical coherence tomography SP - 139 EP - 151 JF - Journal of neurology JO - J. Neurol. VL - 264 IS - 1 N2 - Antibodies against conformation-dependent epitopes of myelin-oligodendrocyte-glycoprotein (MOG-abs) are present in subgroups of neuromyelitis optica spectrum disorder (NMOSD), recurrent optic neuritis (rON), multiple sclerosis (MS), and anti-NMDAR encephalitis. Using optical coherence tomography (OCT) we assessed whether MOG-abs might serve as potential marker of retinal axonal degeneration. We investigated a clinically heterogeneous cohort of 13 MOG-abs-positive patients (4 MOG-abs-positive rON, 4 MOG-abs-positive adult MS, 3 MOG-abs-positive relapsing encephalomyelitis, 2 MOG-abs-positive aquaporin-4-abs-negative NMOSD). As controls, we studied 13 age, sex and ON episode(s)-matched MOG-abs and aquaporin-4-abs-negative (AQP4-abs-negative) MS patients and 13 healthy controls (HC). In addition, we investigated 19 unmatched AQP4-abs-positive MOG-abs-negative NMOSD subjects. Considering all eyes, global pRNFL [in µm, mean (SD)] was significantly reduced in MOG-abs-positive patients [72.56 (22.71)] compared to MOG-abs-negative MS [80.81 (13.55), p = 0.0128], HCs [103.54 (8.529), p = 0.0014] and NMOSD [88.32 (18.43), p = 0.0353]. Non ON eyes from MOG-abs-positive subjects showed significant subclinical atrophy of temporal pRNFL quadrants. Microcystic macular edema (MME) was observed only in eyes of MOG-abs-positive (24%) and AQP4-abs-positive NMOSD (5.6%), but not in MOG-abs-negative MS or HC (p < 0.01). MOG-abs may serve as potential marker of retinal degeneration. Specifically, MOG-abs-related OCT features predominate in temporal pRNFL quadrants (resembling the MS retinal pattern), might be more severe than AQP4-abs-positive NMOSD, indicate subclinical pathology, and may be associated with MME. SN - 1432-1459 UR - https://www.unboundmedicine.com/medline/citation/27844165/Myelin_oligodendrocyte_glycoprotein__MOG__autoantibodies_as_potential_markers_of_severe_optic_neuritis_and_subclinical_retinal_axonal_degeneration_ L2 - https://dx.doi.org/10.1007/s00415-016-8333-7 DB - PRIME DP - Unbound Medicine ER -